Aromatase inhibitors in post-menopausal metastatic breast carcinoma

Bibliography

• STOCKLER M, WILCKEN NRC, GHERSI D, SIMES RJ: Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat. Rev. (2000) 26:151-168.
   PubMed Web of Science ®Google Scholar
• HALLER DG, FOX KR, SCHUCTER LM: Metastatic breast cancer: In: Breast Cancer Treatment: A Comprehensive Guide To Management. Fowble B, Goodman RL, Glick JH et al. (Eds), Mosby Year Book, St Louis, MO, USA (1991).
   Google Scholar
• FORBES JF: The control of breast cancer: the role of tamoxifen. Semin. Oncol. (1997) 24(Suppl. 1):S5-S19.
   Web of Science ®Google Scholar
• PUJOL P, DAURES JP, THEZENAS S: Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer (1998) 83:698-705.
   PubMed Web of Science ®Google Scholar
• OSBORNE CK, YOCHMOWITZ MG, KNIGHT WA III: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 46:2884-2888.
   PubMed Web of Science ®Google Scholar
• CLARK G, OSBORNE C, MCGUIRE W: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. (1984) 2:1102-1109.
   PubMed Web of Science ®Google Scholar
• BEATSON GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet (1896) 2:104-107.
   Google Scholar
• EARLY BREAST CANCER TRIALISTS’COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet (1998) 351:1451-1467.
   PubMed Web of Science ®Google Scholar
• MILLER WR: Biological rationale for endocrine therapy in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. (2004) 18:1-32.
   PubMed Web of Science ®Google Scholar
• ALI S, COOMBES RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer (2002) 2:101-112.
   PubMed Web of Science ®Google Scholar
• HOWELL A, DOWSETT M: Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res. (2004) 6:269-274.
   PubMed Web of Science ®Google Scholar
• LOVE RR, BARDEN HS, MAZESS RB, EPSTEIN S, CHAPPELL RJ: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. Intern. Med. (1994) 154:2585-2588.
   PubMed Web of Science ®Google Scholar
• EARLY BREAST CANCERTRIALISTS’ COLLABORATIVE GROUP (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 365:1687-1717.
   PubMed Web of Science ®Google Scholar
• FISHER B, DIGNAM J, BRYANT J, WOLMARK N: Five versus more than 5 years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer Inst. (2001) 93:684-690.
   PubMed Web of Science ®Google Scholar
• CUZICK J, POWLES T, VERONESI U et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 361:296-300.
   PubMed Web of Science ®Google Scholar
• BONNETERRE J, THÜRLIMANN BJK, ROBERTSON JFR et al.: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J. Clin. Oncol. (2000) 18:3748-3757.
   PubMed Web of Science ®Google Scholar
• NABHOLTZ JM, BUZDAR A, POLLAK M et al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. (2000) 18:3758-3767.
   PubMed Web of Science ®Google Scholar
• MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. (2001) 19:2596-2560.
   PubMed Web of Science ®Google Scholar
• NELSON LR, BULUN SE: Estrogen production and action. J. Am. Acad. Dermatol. (2001) 45(Suppl. 3):S116-S124.
   PubMedGoogle Scholar
• EVANS CT, LEDESMA DB, SCHULZ TZ, SIMPSON ER, MENDELSON CR: Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P450 mRNA. Proc. Natl. Acad. Sci. USA (1986) 83:6387-6391.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Pharmacology of new aromatase inhibitors. Breast (1996) 5:202-208.
   Web of Science ®Google Scholar
• GEISLER J, KING N, ANKER G et al.: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. (1998) 4:2089-2093.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocr. Relat. Cancer (1999) 6:251-257.
   PubMed Web of Science ®Google Scholar
• BUZDAR AU, ROBERTSON JFR, EIERMANN W, NABHOLTZ JM: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer (2002) 95:2006-2016.
   PubMed Web of Science ®Google Scholar
• MILLER WR: Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev. (1989) 16:83-93.
   PubMed Web of Science ®Google Scholar
• BUZDAR AU, SMITH R, VOGEL C et al.: Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer (1996) 77:2503-2513.
   PubMed Web of Science ®Google Scholar
• THURLIMANN B, CASTIGLIONE M, HSU-SCHMITZ SF et al.: Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a Phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur. J. Cancer (1997) 33:1017-1024.
   PubMed Web of Science ®Google Scholar
• FREUE M, KJAER M, BONI C et al.: Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. Breast (2000) 9:9-16.
   PubMed Web of Science ®Google Scholar
• GOSS PE, WINER EP, TANNOCK IF, SCHWARTZ LH: Randomized Phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J. Clin. Oncol. (1999) 17:52-63.
   PubMed Web of Science ®Google Scholar
• LAMB HM, ADKINS JC: Letrozole: a review of its use in postmenopausal women with advanced breast cancer. Drugs (1998) 56:1125-1140.
   PubMed Web of Science ®Google Scholar
• WISEMAN LR, ADKINS JC: Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging (1998) 13:321-332.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res. Treat. (1998) 49(Suppl. 1):S45-S52.
   PubMed Web of Science ®Google Scholar
• WINER EP, HUDIS C, BURSTEIN HJ et al.: American Society of Clinical Oncology Technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. (2005) 23:619-629.
   PubMed Web of Science ®Google Scholar
• SMITH IE, DOWSETT M, YAP YS et al.: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol. (2006):2444-2447.
   PubMed Web of Science ®Google Scholar
• ELLIS MJ: Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy. Ann. Surg. Oncol. (2004) 11(Suppl. 1):9S-17S
   PubMed Web of Science ®Google Scholar
• ELLIS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. (2001) 19:3808-3816.
   PubMed Web of Science ®Google Scholar
• WITTON CJ, REEVES JR, GOING JJ, COOKE TG, BARTLETT JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. (2003) 200:290-297.
   PubMed Web of Science ®Google Scholar
• RING A, DOWSETT M: Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer (2004) 11:643-658.
   PubMed Web of Science ®Google Scholar
• BAUM M, BUZDAR A: The current status of aromatase inhibitors in the management of breast cancer. Surg. Clin. North Am. (2003) 83:973-994.
   PubMed Web of Science ®Google Scholar
• ALLRED DC, BAUM M, BUZDAR AU et al.: A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J. (2003) 9:213-222.
   PubMedGoogle Scholar
• ROSE C, VTORAYA O, PLUZANSKA A et al.: An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer (2003) 39:2318-2327.
   PubMed Web of Science ®Google Scholar
• LONNING P, BAJETTA E, MURRAY R et al.: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J. Clin. Oncol. (2000) 18:2234-2244.
   PubMed Web of Science ®Google Scholar
• VERGOTE I, ROBERTSON JF, KLEEBERG U, BURTON G, OSBORNE CK, MAURIAC L: Trial 0020 investigators; trial 0021 investigators: postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res. Treat. (2003) 79:207-211.
   PubMed Web of Science ®Google Scholar
• OSBORNE CK: Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J. Steroid Biochem. Mol. Biol. (1993) 47:83-89.
   PubMed Web of Science ®Google Scholar
• CANNEY PA, GRIFFITHS T, LATIEF TN, PRIESTMAN TJ: Clinical significance of tamoxifen withdrawal response. Lancet (1987) 1:36.
   PubMed Web of Science ®Google Scholar
• WITTON CJ, TOVEY SM, WITTON CJ et al.: Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. (2004) 6:R246-R251.
   PubMed Web of Science ®Google Scholar
• TOVEY S, DUNNE B, WITTON CJ, FORSYTH A, COOKE TG, BARTLETT JM: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res. (2005) 11:4835-4842.
   PubMed Web of Science ®Google Scholar
• HOWELL BCRT, DIXON JM, JACKSON J et al.: Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur. J. Cancer (2004) 40:2742-2747.
   PubMed Web of Science ®Google Scholar
• OSBORNE CK, SHOU J, MASSARWEH S, SCHIFF R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res. (2005) 11(Part 2):865-870.
   PubMed Web of Science ®Google Scholar
• SHIN I, MILLER T, ARTEAGA CL: ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin. Cancer Res. (2006) 12(3 Part 2):1008s-1012s.
   PubMed Web of Science ®Google Scholar
• PIETRAS RJ: Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist (2006) 11(7):704-717.
   PubMed Web of Science ®Google Scholar
• BUZDAR AU, JONAT W, HOWELL A et al.: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex Study Group. Cancer (1998) 83:1142-1152.
   PubMed Web of Science ®Google Scholar
• DOMBERNOWSKY P, SMITH I, FALKSON G et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. (1998) 16:453-461.
   PubMed Web of Science ®Google Scholar
• JONAT W, HOWELL A, BLOMQVIST C et al.: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer (1996) 32A:404-412.
   PubMed Web of Science ®Google Scholar
• BUZDAR A, DOUMA J, DAVIDSON N et al.: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. (2001) 19:3357-3366.
   PubMed Web of Science ®Google Scholar
• KAUFMANN M, BAJETTA E, DIRIX LY et al.: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J. Clin. Oncol. (2000) 18:1399-1411.
   PubMed Web of Science ®Google Scholar
• BUZDAR A, HOWELL A: Advances in aromatase inhibition clinical efficacy and tolerability in the treatment of breast cancer. Clin. Cancer Res. (2001) 7:2620-2635.
   PubMed Web of Science ®Google Scholar
• MESSORI A, CATTEL F, TRIPPOLI S, VAIANI M: Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anticancer Drugs (2000) 11:701-706.
   PubMed Web of Science ®Google Scholar
• CARLINI P, BRIA E, GIANNARELLI D et al.: New aromatase inhibitors as second-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomized trials. Cancer (2005) 104(7):1335-1342.
   PubMed Web of Science ®Google Scholar
• GIBSON LJ, DAWSON C, LAWRENCE DJ, BLISS J: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst. Rev. (2007) 1:CD003370.
   PubMedGoogle Scholar
• MAURI D, PAVLIDIS N, POLYZOS NP, IOANNIDIS JP: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J. Natl. Cancer Inst. (2006) 98(18):1285-1291.
   PubMed Web of Science ®Google Scholar
• ROSE C, VTORAYA O, PLUZANSKA A et al.: An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer (2003) 39(16):2318-2327.
   PubMed Web of Science ®Google Scholar
• BONNETERRE J, BUZDAR A, NABHOLTZ JMA et al.: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer (2001) 92:2247-2258.
   PubMed Web of Science ®Google Scholar
• MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. (2003) 21:2101-2109.
   PubMed Web of Science ®Google Scholar
• MILLA-SANTOS A, MILLA L, PORTELLA J et al.: Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, Phase III study. Am. J. Clin. Oncol. (2003) 26:317-322.
   PubMed Web of Science ®Google Scholar
• PARIDAENS R, THERASSE P, DIRIX L et al.: First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – a randomized Phase III trial of the EORTC Breast Group. Proc. Am. Soc. Clin. Oncol. (2004) 23:6.
   Google Scholar
• COHEN MH, JOHNSON JR, LI N, CHEN G, PAZDUR R: Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin. Cancer Res. (2002) 8(3):665-669.
   PubMed Web of Science ®Google Scholar
• FERRETTI G, BRIA E, GIANNARELLI D et al.: Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br. J. Cancer (2006) 94(12):1789-1796.
   PubMed Web of Science ®Google Scholar
• COPUR MS, LEDAKIS P, BOLTON M, NORVELL M, MUHVIC J: Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? Letter 1. J. Clin. Oncol. (2001) 19:2578-2578.
   PubMedGoogle Scholar
• COSTA SD, KAUFMANN M: Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? Letter 5. J. Clin. Oncol. (2001) 19:2580-2580.
   PubMedGoogle Scholar
• TONKIN K: Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? Letter 4. J. Clin. Oncol. (2001) 19:2579-2580.
   PubMed Web of Science ®Google Scholar
• KAUFMANN M, BAJETTA E, DIRIX LY et al.: Exemestane improves survival in metastatic breast cancer: results of a Phase III randomized study. Clin. Breast Cancer (2000) 1(Suppl. 1):S15-S18.
   PubMedGoogle Scholar
• BOEDDINGHAUS IM, DOWSETT M: Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. (2001) 79:85-91.
   PubMed Web of Science ®Google Scholar
• HOWELL A, CUZICK J, BAUM M et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet (2005) 365(9453):60-62.
   PubMed Web of Science ®Google Scholar
• THURLIMANN B, KESHAVIAH A, COATES AS et al.: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. (2005) 353(26):2747-2757.
   PubMed Web of Science ®Google Scholar
• COATES AS, KESHAVIAH A, THURLIMANN B et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of Study BIG 1-98. J. Clin. Oncol. (2007) 25(5):486-492.
   PubMed Web of Science ®Google Scholar
• THURLIMANN B, PARIDAENS R, SERIN D et al.: Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a Phase II multicentre multinational study. Eur. J. Cancer (1997) 33:1767-1773.
   PubMed Web of Science ®Google Scholar
• IAFFAIOLI RV, FORMATO R, TORTORIELLO A et al.: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br. J. Cancer (2005) 92:1621-1625.
   PubMed Web of Science ®Google Scholar
• STEELE N, ZEKRI J, COLEMAN R et al.: Exemestane in metastatic breast cancer: effective therapy after third-generation nonsteroidal aromatase inhibitor failure. Breast (2006) 15(3):430-436.
   PubMed Web of Science ®Google Scholar
• BUNDRED N, HOWELL A: Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev. Anticancer Ther. (2002) 2:151-160.
   PubMed Web of Science ®Google Scholar
• HANstein B, DJAHANSOUZI S, DALL P, BECKMANN MW, BENDER HG: Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur. J. Endocrinol. (2004) 150:243-255.
   PubMed Web of Science ®Google Scholar
• JOHNSTON S: Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br. J. Cancer (2004) 90(Suppl. 1):S15-S18.
   Google Scholar
• INGLE JN, SUMAN VJ, ROWLAND KM et al.: Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol. (2006) 24:1052-1056.
   PubMed Web of Science ®Google Scholar
• JOHNSTON SR, MARTIN LA, DOWSETT M: Life following aromatase inhibitors: where now for endocrine sequencing? Breast Cancer Res. Treat. (2005) 93(Suppl. 1):S19-S25.
   Google Scholar
• GRADISHAR W, CHIA S, PICCART M et al.: Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, Phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res. Treat. (2006) 100(Suppl. 1):12 (Abstract).
   Google Scholar
• SANTEN RJ, SONG RX, ZHANG Z, YUE W, KUMAR R: Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin. Cancer Res. (2004) 10:337S-345S.
   Google Scholar
• THURLIMANN B, ROBERTSON JF, NABHOLTZ JM, BUZDAR A, BONNETERRE J: Arimidex Study Group. Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur. J. Cancer (2003) 39:2310-2317.
   PubMed Web of Science ®Google Scholar
• NABHOLTZ JM, BONNETERRE J, BUZDAR A, ROBERTSON JF, THURLIMANN B: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer (2003) 39:1684-1689.
   PubMed Web of Science ®Google Scholar
• THURLIMANN B, HESS D, KOBERLE D et al.: Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res. Treat. (2004) 85:247-254.
   PubMed Web of Science ®Google Scholar
• GOSS PE, INGLE JN, MARTINO S et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. (2005) 97(17):1262-1271.
   PubMed Web of Science ®Google Scholar
• COOMBES RC, HALL E, GIBSON LJ et al.: Intergroup exemestane study: a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. (2004) 350:1081-1092.
   PubMed Web of Science ®Google Scholar
• COOMBES RC, KILBURN LS, SNOWDON CF et al.: Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 369:559-570.
   PubMed Web of Science ®Google Scholar
• BERTELLI G, GARRONE O, MERLANO M et al.: Sequential treatment with exemestane and nonsteroidal aromatase inhibitors in advanced breast cancer. Oncology (2005) 69:471-477.
   PubMed Web of Science ®Google Scholar
• JAKESZ R, KAUFMANN M, GNANT M et al.: ABCSG and the GABG: switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet (2005) 366:455-462.
   PubMed Web of Science ®Google Scholar
• BURSTEIN HJ, PUNGLIA RS: Choosing the best adjuvant endocrine treatment strategy for patients with postmenopausal breast cancer: a decision analysis. In: ASCO 2005 Educational Book. Perry MC (Ed.), ASCO, Alexandria, VA, USA (2005):40-44.
   Google Scholar
• PUNGLIA RS, KUNTZ KM, WINER EP, WEEKS JC, BURSTEIN HJ: Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J. Clin. Oncol. (2005) 23:5178-5187.
   PubMed Web of Science ®Google Scholar
• HOWELL A, PIPPEN J, ELLEDGE RM et al.: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer (2005) 104(2):236-239.
   PubMed Web of Science ®Google Scholar
• INGLE JN, SUMAN VJ, ROWLAND KM et al.; NORTH CENTRAL CANCER TREATMENT GROUP TRIAL N0032: Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol. (2006) 24(7):1052-1056.
   PubMed Web of Science ®Google Scholar
• ROBERTSON JF, HOWELL A, GORBUNOVA VA, WATANABE T, PIENKOWSKI T, LICHINITSER MR: Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res. Treat. (2005) 92:169-174.
   PubMed Web of Science ®Google Scholar
• HOWELL A, ROBERTSON JF, ABRAM P et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. (2004) 22:1605-1613.
   PubMed Web of Science ®Google Scholar
• DRANITSARIS G, VERMA S, TRUDEAU M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. Oncol. (2003) 26(3):289-296.
   PubMed Web of Science ®Google Scholar
• MARCHETTI M, CARUGGI M, COLOMBO G: Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin. Ther. (2004) 26:1546-1546.
   PubMed Web of Science ®Google Scholar
• KARNON J, JONES T: A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. Pharmacoeconomics (2003) 21(7):513-525.
   PubMed Web of Science ®Google Scholar
• KARNON J, JOHNSTON SR, JONES T, GLENDENNING A: A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann. Oncol. (2003) 14(11):1629-1633.
   PubMed Web of Science ®Google Scholar
• WILCKEN N, HORNBUCKLE J, GHERSI D: Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. (2003) 2:CD002747.
   PubMedGoogle Scholar
• FOSSATI R, CONFALONIERI C, TORRI V et al.: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. (1998) 16:3439-3460.
   PubMed Web of Science ®Google Scholar
• BERTELLI G, GARRONE O, BERTOLOTTI L et al.: Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology (2005) 68:364-370.
   PubMed Web of Science ®Google Scholar
• MARCOM PK, ISAACS C, HARRIS L et al.: The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. (2006) (In Press).
   PubMedGoogle Scholar
• MACKEY JR, KAUFMAN B, CLEMENS M et al.: Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. (2006) 100(Suppl. 1):3 (Abstract).
   Google Scholar
• JOHNSTON SR, MARTIN LA, HEAD J, SMITH J, DOWSETT M: Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J. Steroid Biochem. Mol. Biol. (2005) 95:173-181.
   PubMed Web of Science ®Google Scholar
• LEARY A, DOWSETT M: Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Br. J. Cancer (2006) 95:661-666.
   PubMed Web of Science ®Google Scholar
• MATSUO K, HOTTA K, UEOKA H: They also serve who only stand and wait: do individual clinical researchers, too? Hoping for individual patient data as public domain. J. Clin. Oncol. (2005) 23:1334-1335.
   PubMed Web of Science ®Google Scholar
• PIEDBOIS P, BUYSE M: Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J. Clin. Oncol. (2004) 22:3839-3841.
   PubMed Web of Science ®Google Scholar